Orion Oyj – Product Pipeline Review

Global Markets Direct’s, ‘Orion Oyj – Product Pipeline Review – 2016’, provides an overview of the Orion Oyj’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Orion Oyj, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Orion Oyj

The report provides overview of Orion Oyj including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Orion Oyj’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Orion Oyj’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Orion Oyj’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Orion Oyj

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orion Oyj’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Orion Oyj Snapshot 6

Orion Oyj Overview 6

Key Information 6

Key Facts 6

Orion Oyj - Research and Development Overview 7

Key Therapeutic Areas 7

Orion Oyj - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Orion Oyj - Pipeline Products Glance 15

Orion Oyj - Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

Orion Oyj - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Orion Oyj - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Orion Oyj - Drug Profiles 21

(budesonide + formoterol fumarate) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

(fluticasone propionate + salmeterol xinafoate) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

levosimendan 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ODM-201 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

dexmedetomidine hydrochloride 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ODM-109 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ODM-204 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ODM-104 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ODM-108 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ODM-203 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Drugs to Agonize GABA-B Receptor for Central Nervous System Disorders 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ORM-10103 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

ORM-3819 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Inhibit BET Bromodomain for Oncology 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules for Pain 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Orion Oyj - Pipeline Analysis 40

Orion Oyj - Pipeline Products by Target 40

Orion Oyj - Pipeline Products by Route of Administration 42

Orion Oyj - Pipeline Products by Molecule Type 43

Orion Oyj - Pipeline Products by Mechanism of Action 44

Orion Oyj - Recent Pipeline Updates 45

Orion Oyj - Dormant Projects 51

Orion Oyj - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

deramciclane 52

nitecapone 52

ODM-102 52

ODM-106 52

ORM-10921 52

Orion Oyj - Company Statement 53

Orion Oyj - Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Orion Oyj, Key Information 6

Orion Oyj, Key Facts 6

Orion Oyj – Pipeline by Indication, 2016 8

Orion Oyj – Pipeline by Stage of Development, 2016 10

Orion Oyj – Monotherapy Products in Pipeline, 2016 11

Orion Oyj – Combination Treatment Modalities in Pipeline, 2016 12

Orion Oyj – Out-Licensed Products in Pipeline, 2016 13

Orion Oyj – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Orion Oyj – Pre-Registration, 2016 15

Orion Oyj – Phase III, 2016 16

Orion Oyj – Phase II, 2016 17

Orion Oyj – Phase I, 2016 18

Orion Oyj – Preclinical, 2016 19

Orion Oyj – Discovery, 2016 20

Orion Oyj – Pipeline by Target, 2016 40

Orion Oyj – Pipeline by Route of Administration, 2016 42

Orion Oyj – Pipeline by Molecule Type, 2016 43

Orion Oyj – Pipeline Products by Mechanism of Action, 2016 44

Orion Oyj – Recent Pipeline Updates, 2016 45

Orion Oyj – Dormant Developmental Projects,2016 51

Orion Oyj – Discontinued Pipeline Products, 2016 52

Orion Oyj, Subsidiaries 55

List of Figures

List of Figures

Orion Oyj – Pipeline by Top 10 Indication, 2016 8

Orion Oyj – Pipeline by Stage of Development, 2016 10

Orion Oyj – Monotherapy Products in Pipeline, 2016 11

Orion Oyj – Combination Treatment Modalities in Pipeline, 2016 12

Orion Oyj – Out-Licensed Products in Pipeline, 2016 13

Orion Oyj – Pipeline by Top 10 Target, 2016 40

Orion Oyj – Pipeline by Route of Administration, 2016 42

Orion Oyj – Pipeline by Molecule Type, 2016 43

Orion Oyj – Pipeline Products by Top 10 Mechanism of Action, 2016 44

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports